English
Among therapeutic proteins, monoclonal antibodies (mAbs) are meeting a major interest which undoubtedly contributed to the advent of the biopharmaceutical industry with more than 80 products approved. Their domain of therapeutic application is currently driven by oncology or the treatment of immune disorder. Due to their recent introduction as therapeutic agent, the evolution of mAbs consequently to the injection is not yet fully understood. Thus, a significant portion of the patients are reacting differently to the treatment, with for instance the expression of antibodies targeting the therapeutic mAbs injected potentially cancelling the effect of the product. In addition, while the dose used is normalized, previous studies show that the clearance of mAbs is significantly different from patients to patients which suggests the dosage is not necessarily optimal in particular to guarantee a constant exposure to the treatment. The quantification of therapeutic mAbs in biological samples is commonly performed using ELISA immunoassays which are available only for a few mAbs. The constant introduction of novel mAbs requires the complete development of a dedicated assay which uses different materials. In addition, the assays are potentially sensitive to interferences originating from the matrix. In order to address the current limitations of ELISA immunoassay and provide a deeper insight regarding the evolution of therapeutic mAbs after injection to the patient, this research project is aiming for the implementation of an innovative analytical strategy for the simultaneous quantification and structural assessment of mAbs in complex biological matrices. This methodology has the particularity to employ high sensitivity capillary electrophoresis hyphenated to tandem mass spectrometry (CE-MS/MS). This approach relies on an innovative instrumentation in order to provide an optimal specificity as well as sensitivity. Additionally, the CE-MS/MS analysis will allow to investigate the structural integrity of the protein over time consequently to the administration to the patient in order to determine the occurrence of post-translational modifications (PTMs) which may impact the pharmacological properties of the treatment or induce immune reactions for example. Especially, the characteristics provided by the CE separation will enable to study the evolution of the different glycoforms independently to unravel the complex mechanistic influencing therapeutic mAbs based treatments. The strategy developed for this research project will focus primarily on the analysis of the mAbs targeting the tumor necrosis factor (TNF-a) in the serum of patients. Consequently, to the statistical validation of the methodology, the CE-MS/MS approach will be applied to study serum samples originating from patients treated for chronic inflammatory bowel disease such as Crohn disease. The quantitative information and structural characterization obtained from the CE-MS/MS analysis will be correlated with the pathophysiological profile of the patients in order to monitor the relevance of the dosage over an extended period of time. In parallel, the structural information will be used to investigate the occurrence of PTMs with the specific reactions of the patient to the treatment. The information delivered by the CE-MS/MS analysis could reveal crucial aspects regarding the evolution of mAbs after their administration to the patient. The specific monitoring provided will help the practitioner on the dosage used depending on the profile of the patients in order to rationalize the cost of these high-value treatments which represents a significant cost for the national healthcare system. Finally, the transposition of the CE-MS/MS methodology to the analysis of other types of therapeutic mAbs will be implemented in order to demonstrate the transferability of this innovative analytical strategy to other types of mAbs with minimal additional developments.
